LWB1
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more
LWB1 (LWB1) - Net Assets
Latest net assets as of June 2025: €597.44 Million EUR
Based on the latest financial reports, LWB1 (LWB1) has net assets worth €597.44 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€784.68 Million) and total liabilities (€187.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €597.44 Million |
| % of Total Assets | 76.14% |
| Annual Growth Rate | 6.32% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.46 |
LWB1 - Net Assets Trend (2022–2025)
This chart illustrates how LWB1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LWB1 (2022–2025)
The table below shows the annual net assets of LWB1 from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €597.44 Million | +24.38% |
| 2024-06-30 | €480.36 Million | -4.28% |
| 2023-06-30 | €501.84 Million | +0.96% |
| 2022-06-30 | €497.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LWB1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27198700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.61 Billion | 269.21% |
| Total Equity | €597.44 Million | 100.00% |
LWB1 Competitors by Market Cap
The table below lists competitors of LWB1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hiwin Technologies Corp
TW:2049
|
$1.96 Billion |
|
DO & CO AG
IS:DOCO
|
$1.96 Billion |
|
SUZHOU KEMATEK INC
SHE:301611
|
$1.96 Billion |
|
Lingbao Gold Group Company Ltd
F:LI9
|
$1.96 Billion |
|
AP Memory Technology Corp
TW:6531
|
$1.95 Billion |
|
Wacoal Holdings Corp
PINK:WACLY
|
$1.95 Billion |
|
LandBridge Company LLC
NYSE:LB
|
$1.95 Billion |
|
AvidXchange Holdings Inc
NASDAQ:AVDX
|
$1.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LWB1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 480,355,000 to 597,442,000, a change of 117,087,000 (24.4%).
- Net loss of 102,142,000 reduced equity.
- New share issuances of 161,205,000 increased equity.
- Other factors increased equity by 58,024,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-102.14 Million | -17.1% |
| Share Issuances | €161.21 Million | +26.98% |
| Other Changes | €58.02 Million | +9.71% |
| Total Change | €- | 24.38% |
Book Value vs Market Value Analysis
This analysis compares LWB1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 26.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 17.38x to 26.99x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €0.73 | €12.60 | x |
| 2023-06-30 | €0.58 | €12.60 | x |
| 2024-06-30 | €0.42 | €12.60 | x |
| 2025-06-30 | €0.47 | €12.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LWB1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -593.92%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.31x
- Recent ROE (-17.10%) is above the historical average (-17.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -18.38% | -894.59% | 0.02x | 1.33x | €-141.05 Million |
| 2023 | -16.32% | -1091.71% | 0.01x | 1.33x | €-132.07 Million |
| 2024 | -18.31% | -1490.27% | 0.01x | 1.39x | €-135.99 Million |
| 2025 | -17.10% | -593.92% | 0.02x | 1.31x | €-161.89 Million |
Industry Comparison
This section compares LWB1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LWB1 (LWB1) | €597.44 Million | -18.38% | 0.31x | $1.96 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |